Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Hopes Eye Drug Beovu Bounces Back After New Approval

Gets EU Okay For Diabetic Macular Edema

Executive Summary

Having struggled to allay safety concerns for its use in wet age-related macular degeneration, the Swiss major has faith Beovu's efficacy and less frequent dosing will prove more than a match for established DME rival Eylea and newcomer Vabysmo.

You may also be interested in...



Keeping Track: GSK’s Priorix Makes Three Novel US FDA CBER Approvals In 2022; Two CV Drugs Among Recent NDAs

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Shilpa Medicare’s Plan For Eylea Biosimilar Spells Ambition, But Path Not Easy

Shilpa Medicare’s plan for trials of an Eylea biosimilar shows the company’s ambition to leapfrog to a biosimilars-led growth strategy, one that Indian majors like Cipla and Lupin pivoted to post a successful generics program. However, the path isn’t going to be easy and Biocon/Viatris, Samsung Biologics are ahead

Carogra, Xenpozyme Among Japan World-First Approvals

The latest batch of new drug approvals in Japan includes several products receiving their first marketing clearances globally, notably a new oral competitor to a blockbuster ulcerative colitis drug and a high-need therapy for the rare disease ASMD.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel